What You Should Know: Berkeley SkyDeck, the global hub for entrepreneurship and a leading accelerator, today announced that it has welcomed the first three companies for its new SkyDeck LSEC Bio Track: AsparaGlue, Editpep, and MZR Neurotech.The inaugural track, created in partnership with the UC Berkeley Life Sciences Entrepreneurship Center (LSEC) through LSEC’s new Venture Grant Program, will assist the UC Berkeley faculty-led teams to launch their own biotech and life sciences
Read More
genomics
Quest Diagnostics Acquires Haystack Oncology for $300M in Cash
What You Should Know: Quest Diagnostics has reached an agreement to acquire Haystack Oncology an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisionsUnder the terms of the agreement, Quest will pay $300 million in cash at closing, net of cash acquired, and up to an additional $150 million on achieving future performance
Read More
Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care
What You Should Know: - A recent study published in JAMA found that conventional genomic tests commonly used for breast cancer tumors can be less accurate for Black women. This news comes at a time when Black women with breast cancer are experiencing mortality rates that are 41% higher than white women. - Dr. Nathalie Johnson, MD FACS and President of The American Society of Breast Cancer Surgeons is among numerous doctors who advocate for Agendia and its tests which look beyond race,
Read More
NVIDIA Unveils Generative AI Service to Advance Life Sciences R&D
What You Should Know: - NVIDIA today announced an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics. - Part of NVIDIA AI Foundations, the new BioNeMo™ Cloud service offering — for both AI model training and inference — accelerates the most time-consuming and costly stages of drug discovery. It
Read More
The Market Demand for Data-Driven Tech Solutions in Healthcare
The market demand for data-driven technology solutions in healthcare is on the rise. Today, one-third of the world's data is generated by the healthcare industry. This data is often complex and is coming from multiple different sources such as personal health information, claims data, clinical trial data, patient surveys, disease registries, population health statistics, wellness apps, and wearable devices. And so, the need for data management technologies continues to grow. In the Future Health
Read More
C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan
What You Should Know: - C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis of next-generation sequencing and exomes. The two companies have entered a collaboration agreement to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research. - Under this agreement, RG will work with C2i Genomics to commercialize
Read More
What Impact Could AI Have On Genetic Testing?
The sequencing and analysis of human DNA have advanced significantly since the initial draft of a human genome that was published as part of the Human Genome Project. With DNA sequencing becoming increasingly cost-effective, the market for genetic testing is growing at an accelerating rate – the market for Next Generation Sequencing (NGS) services has an estimated annual growth of 18.3% from 2022 to 2030. AI presents a range of possibilities for this rapidly growing field, and in this article,
Read More
Tempus Forms Multi-omics Collaboration With Actuate Therapeutics
What You Should Know: - Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone. - This multi-omics approach is being used by Actuate Therapeutics in support
Read More
From Telemedicine to Complete Virtual Care and Beyond
Telemedicine has helped improve the quality of life of patients in every corner of the world and has been successfully utilized to provide convenient care to people with limited or no access to health services. Today, worldwide digital interconnectivity is growing, enabling telehealth to advance health equity, bring access to care for underserved regions and meet the urgent, primary and behavioral healthcare needs of an exploding global population. It has been a remarkable journey for the
Read More
Startup Velsera Launches to Advance Precision Health Through Data-Driven Solutions
What You Should Know: - New company Velsera was announced at the J.P. Morgan Healthcare Conference supported by thematic-focused impact fund Summa Equity (“Summa”). - Velsera sets out to amplify the impact of clinicians, researchers and scientists for the benefit of patients around the world. Velsera creates a software platform out of science, technology, and informatics, making data actionable, accelerating the pace and potential of multi-omics. - Velsera, headquartered in
Read More
